UK move prompts push for Kadcyla in NZ

BCAC is pushing for breakthrough breast cancer drug, Kadcyla, to be publicly funded in New Zealand after a “monumental u-turn” in the UK which has seen the drug funded there.

Debunking the myth of lymphoedema risk

The risk of developing breast cancer-related lymphoedema is associated with a range of factors, not just axillary (armpit) node surgery as is widely believed, a new study reveals.